Bharat Biotech's homegrown COVID-19 vaccine has shown an interim vaccine efficacy of 81% in late-stage clinical trials, the Indian company said on Wednesday.
The interim analysis was based on 43 recorded cases of COVID-19 in the trial of 25,800 participants, conducted in partnership with the Indian government's medical research body.
Thirty-six of the 43 cases were recorded in participants who received a placebo, compared with seven cases in people who were given the Bharat Biotech vaccine, pointing to an efficacy rate of 80.6%, the company said.
India had approved the vaccine, branded COVAXIN, in January without late-stage efficacy data, raising questions about its effectiveness.
India's vaccination drive, currently underway, includes COVAXIN and a vaccine developed by Oxford University and AstraZeneca.
Earlier this week, Indian Prime Minister Narendra Modi was inoculated with the first dose of COVAXIN.
Scottish National Party (SNP) veteran John Swinney was elected as its new leader on Monday and is set to replace Humza Yousaf as Scotland's first minister after he emerged as the sole contender in the contest to pick a new premier.
Israel's military carried out airstrikes in Rafah on Monday, residents said, hours after Israel told Palestinians to evacuate parts of the southern Gaza city where more than a million people uprooted by the war have been sheltering.
Russia said on Monday it would practice the deployment of tactical nuclear weapons as part of a military exercise after what Moscow said were threats from France, Britain, and the United States.